99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 3, 2004, Pages 330-341

  Gabriel, Michael ^a   Froehlich, Franz ^a   Decristoforo, Clemens ^a   Ensinger, Christian ^a   Donnemiller, Eveline ^a   Von Guggenberg, Elisabeth ^a   Heute, Dirk ^a   Moncayo, Roy ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

FDG PET; Scintigraphy; Somatostatin; Technetium 99m; Thyroid carcinoma; Tyrosine octreotide

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; THYROGLOBULIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M EDDA HYNIC TYR(3) OCTREOTIDE; TECHNETIUM 99M EDDA-HYNIC-TYR(3)-OCTREOTIDE; TECHNETIUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TREATMENT PLANNING; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 1542288325     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1376-x     Document Type: Article

References (42)

1. Pacini F, DeGroot LJ. Thyroid neoplasia. In: DeGroot LJ, Jameson JL, eds. Endocrinology, 4th edn. Philadelphia: Saunders; 2001:1541-1566.
2. Ronga G, Fiorentino A, Paserio E, et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post surgical follow-up of differentiated thyroid carcinoma. J Nucl Med 1990; 31:1766-1771.
3. Ozata M, Suzuki S, Miyamoto T, Tsuan Liu RT, Fierro-Renoy F, Degroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79:98-105.
4. Lubin E, Mechli-Frish S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994; 35:257-262.
5. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999; 22 (11 Suppl):3-7.
6. Feine U, Lietzenmayer R, Hanke JP, Held J, Woehrle H, Mueller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37:1468-1472.
7. 131I scan. J Nucl Med 2001; 42:71-76.
8. 131I scanning results after therapy. J Nucl Med 2001; 42:1464-1469.
9. 99mTc-MIBI in the follow-up of differentiated thyroid carcinomas. Nuklearmedizin 1991; 30:115-124.
10. Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997; 38:348-354.
11. Miyamoto S, Kasagi K, Misaki T, Alam MS, Konishi J. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 1997; 38:352-356.
12. Rubello D, Mazzarotte R, Casara D. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 2000; 27:431-440.
13. 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J Nucl Med 2000; 41:631-635.
14. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111-In-DTPA-D-Phe] and [123-I-Tyr]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731.
15. Krenning EP, Kwekkeboom DJ, de Jong M, et al. Essentials of peptide receptor scintigraphy with emphasis on somatostatin analog octreotide. Semin Oncol 1994; 21 (Suppl 13):6-14.
16. Lamberts SWJ, Reubi JC, Krenning EP. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol 1994; 21 (Suppl) 13:1-5.
17. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704-1713.
18. 111In-pentetreotide. J Nucl Med 2001; 42:1134-1138.
19. Tenenbaum F, Lumbroso J, Schlumberger M, Caillou B, Fragu P, Parmentier C. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1995; 36:807-810.
20. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioidine scan. J Clin Endocrinol Metab 1996; 81:2541-2544.
21. Ahlman H, Tisell LE, Wangberg B, et al. The relevance of somatostatin receptors in thyroid neoplasia. Yale J Biol Med 1997; 70:523-533.
22. Gulec SA, Serafini AN, Sridhar KS, et al. Somatostatin receptor expression in Hürthle cell cancer of the thyroid. J Nucl Med 1998; 39:243-245.
23. Garin E, Devillers A, Le Cloirec J, et al. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 1998; 25:687-694.
24. Kolby L, Wangberg B, Ahlman H, et al. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 1998; 22:679-683.
25. Valli N, Catargi B, Ronci N, et al. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 1999; 9:583-589.
26. Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 2001; 24:415-422.
27. Goerges R, Kahaly G, Mueller-Brand J, Maecke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001; 11:647-659.
28. 1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000; 41:636-642.
29. 111In-octreotide. J Nucl Med 2000; 41:1114-1119.
30. 111In-labelled octreotide derivates. Eur J Nucl Med 2000; 27:1318-1325.
31. 111In-DTPA-octreotide for diagnosis of somatostatin receptor expressing tumors. J Nucl Med 2003; 44:708-716.
32. Sobin LH, Wittekind C. International Union Against Cancer. TNM classification of malignant tumours, 5th edn. New York: Wiley-Liss, 1997.
33. American Joint Committee on Cancer. AJCC cancer staging manual, 5th edn. In: Part II: 8. Thyroid Gland. Philadelphia, New York: Lippincott-Raven; 1997:59-61.
34. 3]-octreotide. Bioconjug Chem 1999; 10:431-438.
35. Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 2001; 28:478-482.
36. 18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29:641-647.
37. 18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001; 11:1169-1175.
38. Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 2000; 10:177-183.
39. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000; 62 Suppl 1:84-91.
40. 3-octreotide: a pilot study. Nucl Med Commun 2001; 22:673-678.
41. Hsu CH, Liu FY, Yen RF, Kao CH. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res 2003; 29:9-15.
42. 99mTc-MIBI radio-guided surgery for recurrent thyroid carcinoma: technical feasibility and procedure, and preliminary clinical results. Eur J Nucl Med Mol Imaging 2002; 29:1201-1205.